Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P0ZY
|
|||
| Former ID |
DNCL003131
|
|||
| Drug Name |
Pomaglumetad
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 1 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 2 (mGluR2) | Target Info | Modulator | [2] |
| Metabotropic glutamate receptor 3 (mGluR3) | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glutamatergic synapse | ||||
| Cocaine addiction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group II pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01487083) A Long-Term Study in Schizophrenia. U.S. National Institutes of Health. | |||
| REF 2 | LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr Opin Investig Drugs. 2010 Jul;11(7):833-45. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.